gemcitabine and oxaliplatin

DRUG9 trials

Sponsors

University of Southern California, New Mexico Cancer Research Alliance, Soonchunhyang University Hospital, Shanghai Jiao Tong University School of Medicine, University of Hawaii

Conditions

Adjuvant ChemotherapyAdvanced Biliary Tract AdenocarcinomaCombination ChemotherapyCytokine Release SyndromeDiffuse Large B Cell LymphomaDiffuse Large B-Cell LymphomaERCC1Efficacy

Phase 1

Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)

Active, not recruitingNCT04542824

GenmabDiffuse Large B Cell Lymphoma, Follicular Lymphoma, High-grade B-cell Lymphoma +3

Start: 2020-08-20End: 2027-09-01Updated: 2026-09-09

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

Active, not recruitingNCT04663347

GenmabDiffuse Large B-Cell Lymphoma, Follicular Lymphoma

Start: 2020-11-03End: 2027-09-30Updated: 2026-09-09

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

RecruitingNCT06447376

Taylor BrooksCytokine Release Syndrome, Non-Hodgkin Lymphoma

Start: 2025-01-14End: 2028-09-01Target: 20Updated: 2026-06-25

Phase 2

Clinical Trial of Gemcitabine and Oxaliplatin in Recurrent or Metastatic Breast Cancer

TerminatedNCT00159458

University of Southern CaliforniaMetastastic Breast Cancer, Recurrent Breast Cancer

Start: 2003-07-31End: 2006-12-31Updated: 2014-05-22

Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter

CompletedNCT00250822

New Mexico Cancer Research AllianceLiver Cancer

Start: 2005-10-31End: 2006-07-31Updated: 2011-10-05

A Phase II Study of Gemcitabine With Oxaliplatin as First Line Chemotherapy in Advanced Biliary Tract Cancer

CompletedNCT00504192

Soonchunhyang University HospitalAdvanced Biliary Tract Adenocarcinoma, Combination Chemotherapy, Efficacy +2

Start: 2006-09-30End: 2009-03-31Updated: 2014-05-20

Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1

WithdrawnNCT01524575

University of HawaiiERCC1, Metastatic Pancreatic Cancer

Start: 2012-01-31End: 2014-01-31Updated: 2019-09-25

Phase 3

HAIC Versus Systemic Chemotherapy for Unresectable ICC

Shi MingIntrahepatic Cholangiocarcinoma

Start: 2018-08-01End: 2022-08-01Target: 188Updated: 2019-12-05

Unknown Phase

Impact of Postoperative Adjuvant Chemotherapy in Patients With Hepatocellular Carcinoma After Liver Transplantation

Shanghai Jiao Tong University School of MedicineAdjuvant Chemotherapy, Hepatocellular Carcinoma, Liver Transplantation +2

Start: 2008-12-31End: 2010-12-31Target: 150Updated: 2010-05-18

Related Papers

Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial

The Lancet Haematology2026-08-28

First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma.

2026-08-04

Exposure–Response Analyses to Inform the Optimal Epcoritamab Monotherapy Dosing Regimen in Relapsed or Refractory Follicular Lymphoma

Clinical Pharmacokinetics2026-08-01

Epcoritamab Step-Up Dosing Regimen Selection and Optimization Using Repeated Time-to-Event Modeling for Cytokine Release Syndrome Risk Mitigation.

2026-07-07

Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma.

2026-07-07

Epcoritamab (epcor) + chemoimmunotherapy (CIT) in patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL) eligible for autologous stem cell transplant (ASCT): Pooled results from arms 4 and 10 of EPCORE NHL-2.

Journal of Clinical Oncology2026-05-27

Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial.

2026-03-05

Three-year follow-up of epcoritamab therapy in Japanese patients with relapsed/refractory follicular lymphoma in EPCORE NHL-3.

2026-01-18

Epcoritamab + R-mini-CHOP results in 2-year remissions and high MRD negativity rates in elderly patients with newly diagnosed DLBCL: Results from the EPCORE NHL-2 trial

Blood2025-11-031 citations

Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-3

Blood2025-11-031 citations

Fixed-duration epcoritamab + R-CHOP in patients with newly diagnosed DLBCL and high IPI scores (3–5) led to sustained remissions and disease-free survival beyond 3 years: Results from the EPCORE NHL-2 trial

Blood2025-11-031 citations

Fixed-duration epcoritamab in combination with bendamustine + Rituximab (BR) for first-line (1L) treatment of follicular lymphoma (FL): 3-year results from EPCORE NHL-2 arm 3 demonstrate deep and durable responses with manageable safety

Blood2025-11-03

Cytotoxic CD8⁺ T cells are required for CD20xCD3 bispecific antibody-mediated tumor control in B-cell non-Hodgkin lymphomas

Blood2025-11-03

Epcoritamab + GemOx achieves durable &gt;2-year remissions in relapsed/refractory (R/R) 2L+ diffuse large B-cell lymphoma (DLBCL): Long-term data reinforce clinical potential of the regimen across a diverse patient population

Blood2025-11-03

Phase II investigator-initiated trial of epcoritamab-lenalidomide in treatment naïve follicular lymphoma

Blood2025-11-03

Epcoritamab with rituximab + lenalidomide (R2) and epcoritamab maintenance deliver deep and durable remissions in previously untreated (1L) follicular lymphoma (FL): 3-year outcomes from epcore NHL-2 arms 6 and 7

Blood2025-11-03

EPCORE FL-2 Phase 3 trial of epcoritamab with rituximab and lenalidomide (R2) vs chemoimmunotherapy (CIT) in previously untreated follicular lymphoma (FL): Trial in progress

Blood2025-11-03

Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma.

2025-11-01

Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Match-Adjusted Comparative Analysis.

2025-10-13

Subcutaneous epcoritamab monotherapy in Japanese patients with relapsed or refractory follicular lymphoma: primary results of the EPCORE NHL-3 trial

Leukemia & lymphoma/Leukemia and lymphoma2025-07-091 citations

49 more papers not shown